Soluble hybrid Fcγ receptors and related methods

• US 9,663,566 B2
• Filed: 12/17/2013
• Issued: 05/30/2017
• Est. Priority Date: 06/27/2008
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Birks, Carl W, Fox, Brian A, Rixon, Mark W, Ellsworth, Jeff L
• Primary Examiner(s): DAHLE, CHUN WU
• Application Number:
  US14/109,165
• Publication Number:
  US 20140107034A1
• Time in Patent Office: 1,260 Days
• Field of Search: None
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 14/70535 Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Abstract

Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides.

Claims

1. An isolated, soluble polypeptide comprising an amino acid sequence selected from the group consisting of

amino acid residues 43-310 of SEQ ID NO:

42;

amino acid residues 21-286 of SEQ ID NO;

44; and

amino acid residues 21-286 of SEQ ID NO;

46;

wherein said polypeptide is capable of specifically binding the Fc region of IgG.

2. The polypeptide of claim 1, further comprising a secretory signal sequence.

3. A composition comprising:

an isolated polypeptide as in claim 1; and

a pharmaceutically acceptable vehicle.